person · Reporting owner

Harsch Mutya

Disclosed activity across 3 companies

Tapewire entity: 28716
SEC CIK: 0001727809

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Yarrow Bioscience, Inc.VYNE · Entity 6871	CHIEF LEGAL OFFICER AND GC	July 23, 2026	July 24, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Yarrow Bioscience, Inc.

Report date July 23, 2026 · Filed July 24, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	95,918	Reported balance After 2026-07-23 transaction · row 1 1 source row Row 1 · 2026-07-23 · Tax withholding · Disposed 22,516 · Balance 95,918 F1: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Foamix Pharmaceuticals Ltd.

Report date March 09, 2020 · Filed March 11, 2020

Section 16 reporting ended · disclosed 2020-03-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	Ending reported balance After 2020-03-09 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2020-03-09 · Disposition to issuer · Disposed 12,742 · Balance 85,490 F1: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2) F2: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement. Row 2 · 2020-03-09 · Disposition to issuer · Disposed 85,490 · Balance 0 F3: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR.
OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $6.35 · Expires 2028-02-27	Direct	Reported balance After 2020-03-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-03-09 · Disposition to issuer · Disposed 50,000 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F4: The ordinary shares underlying this option vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending March 31, 2022.
OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.77 · Expires 2029-01-01	Direct	Reported balance After 2020-03-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-03-09 · Disposition to issuer · Disposed 70,297 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F6: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2020 and 6.25% every three months thereafter) ending March 31, 2023.
OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $4.03 · Expires 2030-02-24	Direct	Reported balance After 2020-03-09 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-03-09 · Disposition to issuer · Disposed 96,365 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F7: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2)

F2: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement.

F3: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR.

F4: The ordinary shares underlying this option vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending March 31, 2022.

F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options.

F6: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2020 and 6.25% every three months thereafter) ending March 31, 2023.

F7: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024.

Satsuma Pharmaceuticals, Inc.

Report date June 08, 2023 · Filed June 08, 2023

Section 16 reporting ended · disclosed 2023-06-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.48	Direct	0	Reported balance After 2023-06-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-08 · Disposition to issuer · Disposed 40,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.46	Direct	0	Reported balance After 2023-06-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-06-08 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes.

F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 31, 2020 Filed Apr 2, 2020 20:47 UTC	Yarrow Bioscience, Inc. MNLO · Entity 6871	Tax withholdingCommon Stock	1,688	$2.68	$4,523.84	Disclosure SEC source: 0001209191-20-022613 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,503 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document
March 09, 2020 Filed Mar 11, 2020 21:56 UTC	Yarrow Bioscience, Inc. MNLO · Entity 6871	GrantStock Options · Derivative	57,086	Not disclosed Strike: $6.81	Not disclosed	Disclosure SEC source: 0001209191-20-018226 · doc4.xml · derivative · entry 5 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,086 Underlying: Common Stock · 57,086 shares Expires 2030-02-24 F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. F5 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024. Read SEC document
March 09, 2020 Filed Mar 11, 2020 21:56 UTC	Yarrow Bioscience, Inc. MNLO · Entity 6871	GrantStock Options · Derivative	41,643	Not disclosed Strike: $6.37	Not disclosed	Disclosure SEC source: 0001209191-20-018226 · doc4.xml · derivative · entry 4 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,643 Underlying: Common Stock · 41,643 shares Expires 2029-01-01 F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. F4 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2020 and 6.25% every three months thereafter) ending March 31, 2023. Read SEC document
March 09, 2020 Filed Mar 11, 2020 21:56 UTC	Yarrow Bioscience, Inc. MNLO · Entity 6871	GrantStock Options · Derivative	29,620	Not disclosed Strike: $10.73	Not disclosed	Disclosure SEC source: 0001209191-20-018226 · doc4.xml · derivative · entry 3 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,620 Underlying: Common Stock · 29,620 shares Expires 2028-02-27 F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. F3 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending March 31, 2022. Read SEC document
March 09, 2020 Filed Mar 11, 2020 21:56 UTC	Yarrow Bioscience, Inc. MNLO · Entity 6871	GrantCommon Stock	50,643	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-018226 · doc4.xml · nonDerivative · entry 2 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,191 F2 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo. F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. Read SEC document
March 09, 2020 Filed Mar 11, 2020 21:56 UTC	Yarrow Bioscience, Inc. MNLO · Entity 6871	GrantCommon Stock	7,548	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-018226 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,548 F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. Read SEC document
March 09, 2020 Filed Mar 11, 2020 17:39 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	Disposition to issuerOptions · Derivative	96,365	Not disclosed Strike: $4.03	Not disclosed	Disclosure SEC source: 0001209191-20-018196 · doc4.xml · derivative · entry 5 Harsch Mutya · CIK 0001727809 · CLO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 96,365 shares Expires 2030-02-24 F5 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F7 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024. Read SEC document
March 09, 2020 Filed Mar 11, 2020 17:39 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	Disposition to issuerOptions · Derivative	70,297	Not disclosed Strike: $3.77	Not disclosed	Disclosure SEC source: 0001209191-20-018196 · doc4.xml · derivative · entry 4 Harsch Mutya · CIK 0001727809 · CLO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 70,297 shares Expires 2029-01-01 F5 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F6 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2020 and 6.25% every three months thereafter) ending March 31, 2023. Read SEC document
March 09, 2020 Filed Mar 11, 2020 17:39 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	Disposition to issuerOptions · Derivative	50,000	Not disclosed Strike: $6.35	Not disclosed	Disclosure SEC source: 0001209191-20-018196 · doc4.xml · derivative · entry 3 Harsch Mutya · CIK 0001727809 · CLO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 50,000 shares Expires 2028-02-27 F5 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F4 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending March 31, 2022. Read SEC document
March 09, 2020 Filed Mar 11, 2020 17:39 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	Disposition to issuerOrdinary Shares	85,490	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-018196 · doc4.xml · nonDerivative · entry 2 Harsch Mutya · CIK 0001727809 · CLO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR. Read SEC document
March 09, 2020 Filed Mar 11, 2020 17:39 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	Disposition to issuerOrdinary Shares	12,742	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-018196 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · CLO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,490 F1 · price: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2) F2 · price: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement. Read SEC document
March 02, 2020 Filed Mar 3, 2020 16:38 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	GrantOrdinary Shares	1,761	$2.68	$4,715.08	Disclosure SEC source: 0001209191-20-015237 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · CLO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,232 F1 · kind: These shares were acquired under the Foamix Pharmaceuticals Ltd. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2019 and ending on March 2, 2020 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on December 2, 2019 (the first trading day of the offering period). Read SEC document
February 24, 2020 Filed Feb 24, 2020 18:38 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	GrantOptions · Derivative	96,365	$0.00 Strike: $4.03	$0.00	Disclosure SEC source: 0001209191-20-012198 · doc4.xml · derivative · entry 2 Harsch Mutya · CIK 0001727809 · CLO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,365 Underlying: Ordinary Shares · 96,365 shares Expires 2030-02-24 F3 · security: Each option represents a contingent right to purchase one ordinary share of the issuer. F4 · derivative.exercise_date: The ordinary shares underlying these options vest over a 4 year period, with 25% vesting on the first anniversary of the last day of the calendar quarter in which the grant occurred and 6.25% vesting on the last day of each subsequent calendar quarter, ending March 31, 2024. Read SEC document
February 24, 2020 Filed Feb 24, 2020 18:38 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	GrantOrdinary Shares	41,299	$0.00	$0.00	Disclosure SEC source: 0001209191-20-012198 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · CLO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,471 F1 · security: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. F2 · shares: The ordinary shares underlying this restricted share unit award vest over a 4 year period, with 25% vesting on the first anniversary of the last day of the calendar quarter in which the grant occurred and 6.25% vesting on the last day of each subsequent calendar quarter, ending March 31, 2024. Read SEC document
December 31, 2019 Filed Jan 3, 2020 17:23 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	Tax withholdingOrdinary Shares	618	$3.28	$2,027.04	Disclosure SEC source: 0001209191-20-001240 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · CLO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,172 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of the restricted share units and does not represent a sale by the Reporting Person. Read SEC document
November 29, 2019 Filed Dec 3, 2019 16:30 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	GrantOrdinary Shares	4,284	$2.16	$9,249.16	Disclosure SEC source: 0001209191-19-058711 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · CLO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,790 F1 · kind: These shares were acquired under the Foamix Pharmaceuticals Ltd. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on June 1, 2019 and ending on December 1, 2019 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on June 3, 2019 (the first trading day of the offering period). Read SEC document
September 30, 2019 Filed Oct 2, 2019 16:19 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	Tax withholdingOrdinary Shares	463	$3.07	$1,421.41	Disclosure SEC source: 0001209191-19-051666 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · CLO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,506 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of the restricted share units and does not represent a sale by the Reporting Person. Read SEC document
July 01, 2019 Filed Jul 3, 2019 16:28 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	SaleOrdinary Shares	639	$2.35	$1,501.65	Disclosure SEC source: 0001209191-19-041111 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · CLO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,969 F1 · security: For administrative reasons, the Reporting Person's then-existing long term incentives were amended in December 2018 to provide that, effective as of January 1, 2019, the vesting of any unvested restricted share units or options that were granted pursuant to such awards shall take place at the end of the calendar quarter in which the award was otherwise scheduled to vest. F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document
April 01, 2019 Filed Apr 3, 2019 16:42 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	SaleOrdinary Shares	2,519	$3.75	$9,446.25	Disclosure SEC source: 0001209191-19-023194 · doc4.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · CLO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,608 F1 · security: For administrative reasons, the Reporting Person's then-existing long term incentives were amended in December 2018 to provide that, effective as of January 1, 2019, the vesting of any unvested restricted share units or options that were granted pursuant to such awards shall take place at the end of the calendar quarter in which the award was otherwise scheduled to vest. F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document
January 01, 2019 Filed Jan 3, 2019 16:06 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	GrantOption (right to buy) · Derivative	70,297	$3.77 Strike: $3.77	$265,019.69	Disclosure SEC source: 0001178913-19-000046 · zk1922433.xml · derivative · entry 2 Harsch Mutya · CIK 0001727809 · CLO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,297 Underlying: Ordinary Shares · 70,297 shares Expires 2029-01-01 F2 · derivative.exercise_date: The ordinary shares underlying these options vest over a period of four years from the end of the calendar quarter in which the grant was made (25% on March 31, 2020, and 6.25% every three months thereafter on the last day of the quarter) ending March 31, 2023, subject to the reporting person's continuous service with the Issuer as of each such vesting date. Read SEC document
January 01, 2019 Filed Jan 3, 2019 16:06 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	GrantOrdinary Shares	30,127	$0.00	$0.00	Disclosure SEC source: 0001178913-19-000046 · zk1922433.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · CLO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,127 F1 · shares: These shares are represented by restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer. The ordinary shares underlying this re-stricted share unit award vest over a period of four years from the end of the calendar quarter in which the grant was made (25% on March 31, 2020, and 6.25% every three months thereafter on the last day of the quarter) ending March 31, 2023, subject to the reporting person's continuous service with the Issuer as of each such vesting date. Read SEC document
February 27, 2018 Filed Feb 28, 2018 16:07 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	GrantOptions · Derivative	50,000	$6.35 Strike: $6.35	$317,500.00	Disclosure SEC source: 0001178913-18-000720 · zk1821306.xml · derivative · entry 2 Harsch Mutya · CIK 0001727809 · General Counsel and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Ordinary Shares · 50,000 shares Expires 2028-02-27 F3 · security: Each option represents a contingent right to purchase one ordinary share of the issuer. F4 · derivative.exercise_date: The ordinary shares underlying these options vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022. Read SEC document
February 27, 2018 Filed Feb 28, 2018 16:07 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	GrantOrdinary Shares	25,000	$0.00	$0.00	Disclosure SEC source: 0001178913-18-000720 · zk1821306.xml · nonDerivative · entry 1 Harsch Mutya · CIK 0001727809 · General Counsel and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F2 · shares: The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022. F1 · price: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.